Skip to content

Educational reference only. Not medical advice. Nothing on this site is for sale.

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

Peptide CompendiumLanguageSign in

Learn

Background guides that make the compound pages easier to read.

Peptides 101

What peptides are, how they are made, why most are injected and how they are modified to last longer.

Reading the research

Cell, animal and human studies; trial phases; and how to tell strong evidence from weak.

Legal status of peptides

FDA approval, compounding lists, "research use only", sports rules and import rules.

Quality and lab testing

How to read a certificate of analysis and what independent testing has found.

Safety

Risks shared across peptides, from contamination to unknown long-term effects.

Storage and stability

Why peptides break down and how labs keep them stable.

Reconstitution guide

How lyophilized peptides are dissolved, and the math behind concentration.

Syringes and units

How U-100 insulin-syringe units relate to milliliters and milligrams.

Reconstitution calculator

Enter vial size, water volume and amount to see concentration and syringe units.

Glossary

Plain-English definitions of the terms used across this site.

FAQ

Short, sourced answers to the most common questions.

News and updates

Dated FDA, compounding, WADA and trial changes, each with its official source.

Reconstitution simulator

Practice vial, water and syringe math with an animated vial and syringe.

Research articles

Sourced articles on peptide science, health and policy from our research desk.